| Amphotericin B inhibits entry of Leishmania donovani into primary macrophages. | |
| | |
MedLine Citation:
|
PMID: 20678487 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Visceral leishmaniasis is a vector-borne disease caused by an obligate intra-macrophage protozoan parasite Leishmania donovani. The molecular mechanisms involved in internalization of Leishmania are still poorly understood. Amphotericin B and its formulations are considered as the best existing drugs against visceral leishmaniasis and are being increasingly used. The reason for its antileishmanial activity is believed to be its ability to bind ergosterol found in parasite membranes. In case of in vivo amphotericin B treatment, both host macrophages and parasites are exposed to amphotericin B. The effect of amphotericin B treatment could therefore be due to a combination of its interaction with both sterols i.e., ergosterol of Leishmania and cholesterol of host macrophages. We report here that cholesterol complexation by amphotericin B markedly inhibits binding of L. donovani promastigotes to macrophages. These results represent one of the first reports on the effect of amphotericin B on the binding of Leishmania parasites to host macrophages. Importantly, these results offer the possibility of reevaluating the mechanism behind the effectiveness of current therapeutic strategies that employ sterol-complexing agents such as amphotericin B to treat leishmaniasis. |
| | |
Authors:
|
Yamuna Devi Paila; Bhaskar Saha; Amitabha Chattopadhyay |
Related Documents
:
|
7755507 - Soluble il-4 receptor, potential for therapeutic and prophylactic intervention. 20802937 - Cytokine expression in the duodenal mucosa of patients with visceral leishmaniasis. 22395097 - Historical overview of immunological tolerance. 19440357 - Leishmania infantum amastigotes enhance hiv-1 production in cocultures of human dendrit... 8023267 - Acute skin injury releases neutrophil chemoattractants. 10453017 - Partial il-10 inhibition of the cell-mediated immune response in chronic beryllium dise... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-08-03 |
Journal Detail:
|
Title: Biochemical and biophysical research communications Volume: 399 ISSN: 1090-2104 ISO Abbreviation: Biochem. Biophys. Res. Commun. Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-08-30 Completed Date: 2010-09-14 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0372516 Medline TA: Biochem Biophys Res Commun Country: United States |
Other Details:
|
Languages: eng Pagination: 429-33 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 Elsevier Inc. All rights reserved. |
Affiliation:
|
Centre for Cellular and Molecular Biology, Council of Scientific and Industrial Research, Uppal Road, Hyderabad 500007, India. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Amphotericin B
/
pharmacology*,
therapeutic use Animals Antiprotozoal Agents / pharmacology*, therapeutic use Female Leishmania donovani / drug effects*, physiology Leishmaniasis, Visceral / drug therapy Macrophages, Peritoneal / drug effects*, parasitology Mice Mice, Inbred BALB C |
| Chemical | |
Reg. No./Substance:
|
0/Antiprotozoal Agents; 1397-89-3/Amphotericin B |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Tensin2 reduces intracellular phosphatidylinositol 3,4,5-trisphosphate levels at the plasma membrane...
Next Document: Prediction of protein subcellular localization by weighted gene ontology terms.